This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: November 15, 2007
Last updated: June 27, 2011
Last verified: June 2011

Primary objective:

To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV

Secondary objective:

To evaluate time to progression, 6month survival, overall survival, safety and tolerability of patients with hepatocellular carcinoma treated with the combination chemotherapy of Eloxatin+5-FU/LV

Condition Intervention Phase
Carcinoma, Hepatocellular Drug: Oxaliplatin Drug: Fluorouracil Drug: Leucovorin Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Oxaliplatin + 5-FluoroUracil/Leucovorin (Eloxatin+5-FU/LV) in Patients With Unresectable Hepatocellular Carcinoma

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan [ Time Frame: every 6 weeks ]

Secondary Outcome Measures:
  • Time to Progression (TTP), 6 month survival, overall survival, AFP [ Time Frame: from the signature of Informed Consent up to end of the study ]

Enrollment: 38
Study Start Date: September 2007
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Oxaliplatin
85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
Drug: Fluorouracil
400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
Drug: Leucovorin
200mg/m², Day 1 and Day 2; Every 2 weeks


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Lists of Inclusion and Exclusion criteria:

  • Patients must have histologically confirmed hepatocellular carcinoma
  • Patients must have measurable disease by CT scan
  • Have not received previous palliative systemic chemotherapy for metastatic disease. (Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.)
  • Patients progress after previous local treatment and at the time of randomization is at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion, Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 4 weeks after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target lesion.
  • WHO 0-2 grades (Karnofsky Performance Score ≥ 70)
  • Patients must have adequate organ and marrow function:

    • Neutrophilus ≥ 1.5 x 10^9/L
    • Platelets ≥ 75 x 10^9/L
    • Asparagine AminoTransferase, Alanine AminoTransferase < 2.5 x Upper Normal Limit(UNL)
    • Total Bilirubin ≤ 1.5 x UNL
    • International Normalized Ratio < 1.5
    • Child stage A or B
    • Creatinine ≤ 1.5 X UNL

Exclusion Criteria:

  • Documented allergy to platinum compound or to other study drugs.
  • Active Gastro-Intestinal bleeding and active haematologic malignancy
  • Previous liver transplantation.
  • Patients concomitantly receiving any other anti-cancer therapy.
  • Patients who are receiving any other study treatments.
  • Pregnant or lactating women or women of childbearing potential without proper contraceptive methods.
  • History of other malignant diseases, except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
  • Central nervous system metastasis
  • Other serious illness or medical conditions
  • Neuropathy ≥ grade 2

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00559455

Korea, Republic of
Sanofi-Aventis Administrative Office
Seoul, Korea, Republic of
Sponsors and Collaborators
Study Director: Hyang Rim Kim Sanofi
  More Information

Responsible Party: Medical Affairs Study Director, Sanofi-aventis Korea Identifier: NCT00559455     History of Changes
Other Study ID Numbers: OXALI_L_02859
Study First Received: November 15, 2007
Last Updated: June 27, 2011

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on August 23, 2017